Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation

References

• Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012;59:222–231.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertensiondagger. Eur Heart J. 2016;37:942–954.
   PubMed Web of Science ®Google Scholar
• Lundgren J, Soderlund C, Radegran G. Impact of postoperative pulmonary hypertension on outcome after heart transplantation. Scand Cardiovasc J. 2017;51:172–181.
   PubMed Web of Science ®Google Scholar
• Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998;82:609–614.
   PubMed Web of Science ®Google Scholar
• Visser M, Paulus WJ, Vermeulen MA, et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail. 2010;12:1274–1281.
   PubMed Web of Science ®Google Scholar
• Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664–666.
   PubMed Web of Science ®Google Scholar
• Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34:906–911.
   PubMed Web of Science ®Google Scholar
• Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62:2425–2430.
   PubMed Web of Science ®Google Scholar
• Hsu CP, Lin SJ, Chung MY, et al. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis. 2012;225:504–510.
   PubMed Web of Science ®Google Scholar
• Zairis MN, Patsourakos NG, Tsiaousis GZ, et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart. 2012;98:860–864.
   PubMed Web of Science ®Google Scholar
• Palm F, Onozato ML, Luo Z, et al. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227–H3245.
   PubMed Web of Science ®Google Scholar
• Quitter F, Figulla HR, Ferrari M, et al. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin Hemorheol Microcirc. 2013;54:75–85.
   PubMed Web of Science ®Google Scholar
• Holm T, Aukrust P, Aagaard E, et al. Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation. 2002;74:1395–1400.
   PubMed Web of Science ®Google Scholar
• Potena L, Fearon WF, Sydow K, et al. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Transplantation. 2008;85:827–833.
   PubMed Web of Science ®Google Scholar
• Sandqvist A, Schneede J, Kylhammar D, et al. Plasma L-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction. Heart Vessels. 2018;33:255–263.
   PubMed Web of Science ®Google Scholar
• Henrohn D, Sandqvist A, Egerod H, et al. Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. Vascul Pharmacol. 2015;73:71–77.
   PubMed Web of Science ®Google Scholar
• Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–1720.
   PubMed Web of Science ®Google Scholar
• Seljeflot I, Nilsson BB, Westheim AS, et al. The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. J Card Fail. 2011;17:135–142.
   PubMed Web of Science ®Google Scholar
• Shao Z, Wang Z, Shrestha K, et al. Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol. 2012;59:1150–1158.
   PubMed Web of Science ®Google Scholar
• Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004;134(10 Suppl):2842S–2847S.
   Web of Science ®Google Scholar
• Creager MA, Gallagher SJ, Girerd XJ, et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248–1253.
   PubMed Web of Science ®Google Scholar
• Boger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592–1600.
   PubMed Web of Science ®Google Scholar
• Anderssohn M, Rosenberg M, Schwedhelm E, et al. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. J Card Fail. 2012;18:904–911.
   PubMed Web of Science ®Google Scholar
• Tang WH, Shrestha K, Wang Z, et al. Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure. J Card Fail. 2013;19:87–93.
   PubMed Web of Science ®Google Scholar
• Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98:334–343.
   PubMed Web of Science ®Google Scholar
• Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation. 1996;93:2135–2141.
   PubMed Web of Science ®Google Scholar
• Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295:58–64.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene S, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251–2262.
   PubMed Web of Science ®Google Scholar
• Lundgren J, Radegran G. Hemodynamic characteristics including pulmonary hypertension at rest and during exercise before and after heart transplantation. J Am Heart Assoc. 2015;4:e001787. doi:10.1161/JAHA.115.001787
   PubMed Web of Science ®Google Scholar
• Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974–982.
   PubMed Web of Science ®Google Scholar